Icon
+91 94997 68112
Login Register

NEXAVAR (nda021923)- (EQ 200MG BASE)

SORAFENIB TOSYLATE BAYER HLTHCARE
EQ 200MG BASE
Yes No
2028-Sep-10 Expired
None None
None No
NEXAVAR is a kinase inhibitor indicated for the treatment of • Unresectable hepatocellular carcinoma • Advanced renal cell carcinoma.
5 0 5
Total Other Developers 14
Drugs with Suitability No
EQ 200MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 5
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ***** ***** ****** ******* *********** **** **.: ** & **, ****, ***** ****** ****, ********, *************, ****** ******* ******, ***** (***) ***
****** ** ****** **.*****'* ************ ******* *********** ** ** ** & ** ** **, ***** - ***, ****, *******,, *************, ****** ******* *** ***, ***** (***) ***
****** ***** ***** ***** ************** **., ***. ******* *********** ** ******** **** *** ******, ***, *******, ******, ***** (***) ***
****** ***** ***** *** ***************, ***. ******* ***** *********** *-*, ******* *** **., ******* ****, ******, ****** (***) ***
****** **** ****** *** *** **** ************** ********** ***. *********** ** *** ******* ******, ********** ****, **** ****, *******, ****** (***) ***
****** ******* ******* *************** ******* *********** **** -*, ****** **. ***, ***, ***, *** ** ***, ********* - ******* *******, *************,****** - *****, ***********, ******* ******, ***** (***) ***

Download GenUS Drug Report

Download GenUS Detailed Report

To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.